GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on developing an ophthalmology drug. Its price chart is a dramatic story of FDA rejection and subsequent attempts to gain approval, exemplifying the binary risks of biotech.
Share prices of companies in the market segment - Pharma eyes
Outlook Therapeutics is a biopharmaceutical company developing an antibody-based drug for the treatment of retinal diseases such as wet macular degeneration. We've categorized it under "Pharma: Eye." The chart below shows how investors view the ophthalmology sector.
Broad Market Index - GURU.Markets
Outlook Therapeutics is a biopharmaceutical company developing an antibody-based drug for the treatment of retinal diseases such as wet macular degeneration. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
OTLK - Daily change in the company's share price Outlook Therapeutics
For Outlook Therapeutics, Inc., which is developing a drug to treat eye diseases, daily volatility reflects sensitivity to FDA decisions. This metric is key to assessing the company's risks following a regulatory waiver.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Outlook Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with OTLK, which focuses on eye disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Outlook Therapeutics is a biotech company specializing in the treatment of eye diseases. Its stock price depends on clinical trial success and regulatory approval. These biotech-specific events create unique price movements that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Outlook Therapeutics
Outlook Therapeutics' year-end performance tells the story of its years-long battle to secure approval for its retinal disease drug. Its market capitalization over the next 12 months depends entirely on the FDA's decisions. Approval for its version of bevacizumab could open up a huge ophthalmology market for the company.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Outlook Therapeutics, Inc. is a biopharmaceutical company developing a drug for the treatment of retinal diseases. Its stock price is entirely dependent on regulatory decisions by the FDA. The chart reflects the high risks and binary nature of the outcome for companies dependent on a single key product.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Outlook is a late-stage biotech whose fate hinges on the approval of its eye drug. Its stock price is completely disconnected from economic cycles. Its chart is a history of binary events: positive regulatory news can trigger a surge, while negative news can cause a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company awaiting approval for its drug for treating retinal diseases. Its monthly performance is entirely dependent on news related to the FDA's decision. Any announcement from the regulator triggers a sharp and strong reaction from investors.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Outlook Therapeutics is focused on the development and commercialization of the ophthalmic drug ONS-5010 for the treatment of retinal diseases such as wet age-related macular degeneration. The chart below reflects sentiment in the ophthalmic pharmaceutical sector, where the need for new treatments is high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Outlook Therapeutics is a biotech company focused on a single drug for the treatment of eye diseases. Its future depends entirely on regulatory approval of this product. Its stock price follows a binary path (success/failure) and is completely unrelated to the broader stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Outlook Therapeutics
Outlook Therapeutics, a biopharmaceutical company aiming for approval of a biosimilar for the treatment of eye diseases, has seen a highly volatile week. Any news from the FDA regarding its application could trigger explosive price movements.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Outlook Therapeutics and the entire late-stage biotech sector are driven by a shared anticipation of regulatory decisions. FDA news is a key driver for everyone. The chart will show how the company fares in this volatile market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Outlook Therapeutics and the entire late-stage biotech sector are driven by a shared anticipation of regulatory decisions. FDA news is a key driver for everyone. The chart will show how the company fares in this volatile market.
Market capitalization of the company, segment and market as a whole
OTLK - Market capitalization of the company Outlook Therapeutics
The Outlook Therapeutics market capitalization chart is the financial valuation of a biotech company seeking FDA approval for its retinal disease drug. It reflects the company's long and winding journey with the regulator. Its volatile dynamics tell the story of how investor hopes collide with the harsh realities of the regulatory process.
OTLK - Share of the company's market capitalization Outlook Therapeutics within the market segment - Pharma eyes
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010, an ophthalmic drug for the treatment of retinal diseases. Its market share reflects its attempt to commercialize a biosimilar of a popular drug. The chart below illustrates the company's weight in the battle for a massive market.
Market capitalization of the market segment - Pharma eyes
Outlook Therapeutics is developing an ophthalmological drug based on bevacizumab. The chart below shows the overall market capitalization of the entire ophthalmology sector. Its dynamics reflect the search for more affordable treatments for retinal diseases. Outlook is seeking approval for a drug that is already widely used off-label.
Market capitalization of all companies included in a broad market index - GURU.Markets
Eye disease treatments, as seen in the chart, represent a huge market. Outlook Therapeutics is trying to bring a cheaper version of Lucentis, a drug for treating retinal diseases. Its market cap is a risky bet on gaining approval and competing with the giants.
Book value capitalization of the company, segment and market as a whole
OTLK - Book value capitalization of the company Outlook Therapeutics
Outlook Therapeutics is investing in the first approved ophthalmic drug, bevacizumab. Currently in the R&D phase, the company is using its financial assets to secure FDA approval for its drug for the treatment of wet macular degeneration.
OTLK - Share of the company's book capitalization Outlook Therapeutics within the market segment - Pharma eyes
Outlook Therapeutics, a biopharmaceutical company, is in the late stages of developing its drug for retinal diseases. Its stake in the sector is minimal. The company is focused on obtaining regulatory approval, outsourcing manufacturing.
Market segment balance sheet capitalization - Pharma eyes
Outlook Therapeutics is a late-stage biopharmaceutical company. Its model is becoming increasingly capital-intensive as it prepares for commercial launch, requiring investments in manufacturing and distribution. Compared to the pharmaceutical sector, its balance sheet reflects this transitional stage.
Book value of all companies included in the broad market index - GURU.Markets
Outlook Therapeutics' assets are not a broad portfolio, but rather focused on developing an ophthalmological version of Avastin for the treatment of retinal diseases. The company's balance sheet reflects the value of this clinical program. The chart shows how much capital is invested in creating a more accessible standard of care.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company aiming for regulatory approval for its drug to treat retinal diseases. Its market capitalization is essentially a barometer of its chances of receiving regulatory approval.
Market to book capitalization ratio in a market segment - Pharma eyes
Outlook Therapeutics is a biotech company seeking approval for its drug to treat eye diseases. Its valuation is almost entirely dependent on regulatory approval. This chart illustrates the high volatility and binary nature of investor bets.
Market to book capitalization ratio for the market as a whole
Outlook Therapeutics is a biopharmaceutical company developing a drug to treat retinal diseases. Its market cap is based on the potential of this single product. The chart shows how the market values such a focused company, where all the risk and potential lie in the success of one key asset.
Debts of the company, segment and market as a whole
OTLK - Company debts Outlook Therapeutics
Outlook Therapeutics is seeking approval for an existing oncology drug to treat eye diseases. Conducting large clinical trials for this new indication requires significant resources. This chart shows how the company is raising capital to finance this regulatory journey.
Market segment debts - Pharma eyes
Outlook Therapeutics is a late-stage biopharmaceutical company seeking approval for its drug to treat retinal diseases. Funding at this stage is critical to completing the regulatory process. This chart shows how the company is using capital to prepare for the potential commercial launch of its first product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Outlook Therapeutics
Outlook Therapeutics develops ophthalmology drugs. This chart shows how much the company relies on debt to bring its key product to market. The path to approval and commercialization in the pharmaceutical industry is long and expensive. High debt means any delay or adverse regulatory decision could be fatal.
Market segment debt to market segment book capitalization - Pharma eyes
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases, aiming to offer a more affordable alternative to existing treatments. This chart compares the company's debt to the overall market capitalization of the sector. It illustrates the financial implications of developing and bringing this important drug to market.
Debt to book value of all companies in the market
Outlook Therapeutics develops ophthalmology drugs. Bringing a new drug to market is a long and expensive process. The chart shows how the company finances its clinical trials and preparation for commercialization. Its debt load, compared to the biotech sector, reflects the financial risks and dependence on the success of its key drug.
P/E of the company, segment and market as a whole
P/E - Outlook Therapeutics
This chart for Outlook Therapeutics, a company developing a drug to treat eye diseases, charts its interactions with the FDA. Investors' assessment of its potential profit hinges entirely on whether the drug receives approval. The dynamics reflect FDA news, which determines the company's fate.
P/E of the market segment - Pharma eyes
This chart reflects the average valuation for the speculative biotech sector—the benchmark for Outlook Therapeutics. Comparison with this metric clearly demonstrates how investors assess the company's risks associated with obtaining regulatory approval. A valuation below the average indicates high market skepticism.
P/E of the market as a whole
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab (known as Avastin) for the treatment of retinal diseases. The company aims to obtain approval for this molecule, which is already widely used but not approved for ophthalmology. This chart shows sentiment in the pharmaceutical sector. It helps understand how the market views this regulatory strategy and the commercial prospects if successful.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Outlook Therapeutics
Outlook Therapeutics is developing an ophthalmological drug based on bevacizumab for the treatment of retinal diseases. The company's future profitability depends on the approval and commercial success of this biosimilar. This chart shows whether analysts believe the company can enter and capture market share in this competitive market.
%20P%2FE%20Outlook%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Outlook-Therapeutics&v=1772629288813 "Chart of the company's future (projected) P/E Outlook Therapeutics")
Future (projected) P/E of the market segment - Pharma eyes
Outlook Therapeutics is developing the ophthalmic drug ONS-5010, a biosimilar of bevacizumab, for the treatment of retinal diseases. This chart compares its future revenue expectations with those of the biotech sector. It demonstrates how the market views its potential to offer a lower-cost alternative to existing treatments and the risks associated with FDA approval.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772629288828 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Outlook Therapeutics is a biopharmaceutical company seeking approval for its drug to treat retinal diseases. This chart shows the overall risk appetite. OTLK's success depends solely on the regulator's decision. This is a binary event that will outweigh any general market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772629288855 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Outlook Therapeutics
Outlook Therapeutics is a late-stage biopharmaceutical company seeking FDA approval for its drug to treat retinal diseases such as wet age-related macular degeneration. This chart shows the company's financial progress toward potential commercialization.
Profit of companies in the market segment - Pharma eyes
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of the ophthalmic drug ONS-5010 for the treatment of retinal diseases such as wet age-related macular degeneration. This chart illustrates the financial climate in the ophthalmic pharmaceutical sector, which is growing due to an aging population and the need for effective treatments.
Overall market profit
Outlook Therapeutics is developing an ophthalmology drug. Like other biotech companies in the development stage, its success depends on clinical trial results and regulatory approval. The need for eye treatments is not dependent on the economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Outlook Therapeutics
Outlook Therapeutics is seeking approval for its drug to treat retinal diseases. It's a huge market, but the company has encountered regulatory challenges. This chart reflects analysts' estimates of the company's chances of bringing its product to market.
%20profit%20of%20the%20company%20Outlook%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Outlook-Therapeutics&v=1772629289179 "Graph of future (projected) profit of the company Outlook Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma eyes
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases such as wet age-related macular degeneration. This chart shows forecasts for the biotech sector. The company's future profitability depends on FDA approval of its drug, which could become a more affordable alternative to existing expensive medications.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772629289225 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Outlook Therapeutics develops ophthalmology drugs. Like any biotech company, it relies on successful clinical trials and subsequent regulatory approval. This graph, which reflects revenue expectations, is an indicator of the overall investment climate, which determines the availability of funding to complete development and bring the product to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772629289238 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Outlook Therapeutics
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This chart shows that the company's valuation is based on the future. It reflects investors' hopes for FDA approval and the potential for its product to become a lower-cost alternative to existing medications.
P/S market segment - Pharma eyes
Outlook Therapeutics is developing the ophthalmic drug ONS-5010, a biosimilar of bevacizumab, for the treatment of retinal diseases such as wet macular degeneration. This chart reflects the average biotech valuation, helping to understand the market's perception of the commercial potential of this drug, which could become a standard of care if approved.
P/S of the market as a whole
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. The company's goal is to obtain approval and offer a more affordable treatment option. This revenue valuation indicator emphasizes that investors are assessing the potential economic benefit of the new drug, not current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Outlook Therapeutics
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This chart reflects investor expectations for the future success of this product. The valuation is based on potential sales revenue if approved, as it could become a cost-effective alternative to existing treatments.
%20P%2FS%20Outlook%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Outlook-Therapeutics&v=1772629289410 "The graph of the company's future (projected) P/S Outlook Therapeutics")
Future (projected) P/S of the market segment - Pharma eyes
Outlook Therapeutics is developing an ophthalmological drug for the treatment of retinal diseases. This chart compares the company's future revenue expectations with its sector. It reflects investors' belief that its drug could become a more affordable alternative to existing, expensive treatments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772629289454 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Outlook Therapeutics is developing and preparing to commercialize an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This chart shows the overall revenue expectations, and Outlook Therapeutics is aiming to capture a huge market. The success of its drug could radically change the standard of care and generate billions in revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772629289512 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Outlook Therapeutics
Outlook Therapeutics is a late-stage biopharmaceutical company seeking approval for its drug to treat retinal diseases. The company currently has no commercial sales revenue. Any revenue reflected in this chart is from licensing agreements.
Sales of companies in the market segment - Pharma eyes
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing the first FDA-approved ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This chart illustrates the dynamics of the pharmaceutical market, where even the development of a new form of a well-known drug can carve out an important market niche.
Overall market sales
Outlook Therapeutics, Inc. is a biopharmaceutical company developing a drug for the treatment of retinal diseases. Its success depends on regulatory approval and commercialization. The growth in total economic revenue, reflected in this graph, impacts the solvency of the healthcare system, which is important for ensuring broad patient access to the new drug once it reaches the market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Outlook Therapeutics
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases such as wet macular degeneration. This timeline reflects analyst expectations for the potential approval and commercial success of this biosimilar in the vast ophthalmology market.
%20sales%20of%20the%20company%20Outlook%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Outlook-Therapeutics&v=1772629289801 "Schedule of future (projected) sales of the company Outlook Therapeutics")
Future (projected) sales of companies in the market segment - Pharma eyes
Outlook Therapeutics is developing and preparing to commercialize an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This chart shows forecasts for the ophthalmic pharmaceutical sector. It illustrates the company's commitment to offering a more affordable and approved treatment option for the mass market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772629289893 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Outlook Therapeutics, which focuses on treating eye diseases, sees this chart as a marker of the stability of the healthcare system. The positive economic forecasts reflected here ensure funding predictability, which is important for the launch and widespread adoption of new ophthalmology drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772629289901 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company seeking FDA approval for its drug for retinal diseases. As it approaches potential commercialization, the company is incurring significant expenses. This chart shows its financial position at this critical stage, reflecting the investments required to bring the product to market.
Market segment marginality - Pharma eyes
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. Their strategy is to obtain regulatory approval for an already widely used (off-label) substance. The effectiveness here lies in the regulatory strategy, not in the discovery of a new molecule.
Market marginality as a whole
Outlook Therapeutics is developing an ophthalmic drug based on bevacizumab for the treatment of retinal diseases. This graph shows the average profitability, and Outlook aims to bring a more affordable therapy to market. Their success depends on regulatory approval and competition from existing drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company seeking to commercialize the first approved drug for retinal diseases. This chart shows its team managing clinical and regulatory processes. Staff growth is inevitable if FDA approval is obtained.
Share of the company's employees Outlook Therapeutics within the market segment - Pharma eyes
Outlook Therapeutics is focused on the development and commercialization of the ophthalmic drug ONS-5010 for the treatment of retinal diseases. This chart shows the percentage of all scientists and clinicians in the ophthalmic pharmaceutical industry that Outlook attracts. This reflects its scientific focus and ambition to bring a new standard of care to market.
Number of employees in the market segment - Pharma eyes
Outlook Therapeutics is a biopharmaceutical company developing an ophthalmological drug for the treatment of retinal diseases. Its staff is focused on clinical development and commercialization preparation. This timeline shows the company's progress toward market entry. Staff growth will be driven by approval and the establishment of a commercial team.
Number of employees in the market as a whole
Outlook Therapeutics develops ophthalmology drugs. The biopharmaceutical industry operates by its own rules. This graph reflects the overall economy, but for Outlook, receiving FDA approval for a new drug to treat retinal diseases will mean a transformation of the business and a sharp increase in staff.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Outlook Therapeutics (OTLK)
Outlook Therapeutics is an ophthalmology R&D company. Its market capitalization reflects investors' hopes for the success of its developments. The very high value on this chart is typical for biotech, where a small team of scientists can create a product worth billions of dollars.
%20of%20the%20company%20Outlook%20Therapeutics%20(OTLK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Outlook-Therapeutics-OTLK&v=1772629290136 "Chart of market capitalization per employee (in thousands of dollars) of the company Outlook Therapeutics (OTLK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Outlook Therapeutics is developing and preparing to commercialize an ophthalmic drug for the treatment of retinal diseases. As a late-stage biotech, its valuation reflects the expected commercial success of its first product. This metric demonstrates the market's confidence in the product, based on the team bringing it to market.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772629290169 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Outlook Therapeutics is a biopharmaceutical company developing a bevacizumab-based drug for the treatment of retinal diseases. Its goal is to obtain approval for a new indication for an existing molecule. The chart shows how the market views a strategy with relatively low scientific risk, where successfully navigating regulatory requirements is crucial.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772629290175 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Outlook Therapeutics (OTLK)
Outlook Therapeutics is a biopharmaceutical company focused on developing an ophthalmic drug (ONS-5010, Bevacizumab) for the treatment of retinal diseases. This is an R&D business. This graph, being negative, shows the investment phase. It reflects how much capital the company invests in each of its scientists.
%20Chart%20Outlook%20Therapeutics%20(OTLK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Outlook-Therapeutics-OTLK&v=1772629290197 "Company Profit Per Employee (in thousands of dollars) Chart Outlook Therapeutics (OTLK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Outlook Therapeutics (OTLK) is a biopharmaceutical company focused on developing and commercializing a drug (bevacizumab) for the treatment of retinal diseases. This chart reflects their path to commercialization. It shows how effectively the team is using capital to overcome regulatory hurdles (FDA) and prepare for product launch.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772629290210 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Outlook Therapeutics is a biotech company seeking to commercialize an approved version of bevacizumab (Avastin) for the treatment of eye diseases. This is not so much an R&D process as a regulatory and commercial one. This chart shows the costs of conducting final trials and preparing for launch. The company's profit per employee will only become positive after FDA approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772629290246 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Outlook Therapeutics (OTLK)
Outlook Therapeutics is a biopharmaceutical company developing a drug for the treatment of retinal diseases. This graph reflects the future potential during the clinical trials and pending approval phase. A sharp increase in revenue per employee will begin after the commercial launch and indicate market demand for their product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Outlook-Therapeutics-OTLK&v=1772629290272 "Sales chart per company employee Outlook Therapeutics (OTLK)")
Sales per employee in the market segment - Pharma eyes
Outlook Therapeutics is a biotech company specializing in the development of an ophthalmic drug (ONS-5010) for the treatment of retinal diseases (wet AMD). This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this competitive field of ophthalmology.
Sales per employee for the market as a whole
Outlook Therapeutics (OTLK) is a biopharmaceutical company focused on commercializing ONS-5010 (bevacizumab) as the first FDA-approved treatment for macular degeneration. This chart shows zero revenue per employee while the company awaits regulatory approval.
Short shares by company, segment and market as a whole
Shares shorted by company Outlook Therapeutics (OTLK)
Outlook Therapeutics is a biopharmaceutical company seeking FDA approval for ONS-5010, the ophthalmic form of Bevacizumab (Avastin). The company has already been rejected. This chart shows the number of investors betting that the company will fail to secure FDA approval due to manufacturing or data issues, which would devalue its only asset.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Outlook-Therapeutics-OTLK&v=1772629290461 "Short Shares Chart for the Company Outlook Therapeutics (OTLK)")
Shares shorted by market segment - Pharma eyes
Outlook Therapeutics is attempting to commercialize an ophthalmic drug (bevacizumab) for the treatment of wet AMD. This chart illustrates the skepticism surrounding this entire niche. Its rise suggests investors are betting heavily against new ophthalmic drugs, anticipating stiff competition or trial failures.
Shares shorted by the overall market
Outlook Therapeutics (OTLK) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing OTLK will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Outlook Therapeutics (OTLK)
Outlook Therapeutics is a single-product biotech targeting FDA approval for its drug to treat retinal diseases. It's a classic binary bet. This oscillator tracks investor sentiment ahead of the regulator's decision: it shows peak optimism (above 70) or deep despair (below 30) after the FDA's decision.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Outlook-Therapeutics-OTLK&v=1772629290543 "RSI 14 indicator chart for the company's stock Outlook Therapeutics (OTLK)")
RSI 14 Market Segment - Pharma eyes
Outlook Therapeutics is a biotech company developing ONS-5010 (ophthalmic bevacizumab) for the treatment of wet macular degeneration (AMD). This chart measures the overall excitement and decline in the ophthalmic biotech sector. It helps separate OTLK volatility from the overall industry trend.
RSI 14 for the overall market
For Outlook Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OTLK (Outlook Therapeutics)
Outlook Therapeutics is seeking FDA approval for ONS-5010 (bevacizumab) as the first officially approved drug for the treatment of wet AMD (an eye disease). This chart shows the analysts' average 12-month price target. Their price target is a bet on the company receiving approval after previous rejections.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OTLK-Outlook-Therapeutics&v=1772629290675 "A chart showing analyst consensus forecasts for the expected stock price. OTLK (Outlook Therapeutics)")
The difference between the consensus estimate and the actual stock price OTLK (Outlook Therapeutics)
Outlook Therapeutics is a biotech company whose sole goal is to obtain FDA approval for ONS-5010, the first officially approved bevacizumab (Avastin) for the treatment of ophthalmic diseases. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the success of this regulatory strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OTLK-Outlook-Therapeutics&v=1772629290729 "A chart showing the difference between the consensus forecast and the actual stock price. OTLK (Outlook Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Outlook Therapeutics (OTLK) is attempting to "legitimize" the off-label practice. The company is seeking FDA approval for ONS-5010, a version of the cancer drug Avastin specifically purified for ocular injections. This chart shows general expectations for the pharmaceutical sector, reflecting whether experts believe this risky regulatory strategy will succeed.
Analysts' consensus forecast for the overall market share price
Outlook Therapeutics is a biotech company developing a "biosimilar" (copy) of Lucentis, a drug for the treatment of wet AMD. This chart shows the company's overall risk appetite. For Outlook, whose value depends on regulatory approval, overall market optimism is important for funding, but FDA news carries far more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Outlook Therapeutics
Outlook Therapeutics (OTLK) is a biotech with one bet: ONS-5010 (Lytenava). It's an ophthalmic (eye) version of the blockbuster drug Avastin, which they're trying to secure first-in-world FDA approval for the treatment of wet macular degeneration. This chart is a summary indicator of their battle with the FDA. Its dynamics are all or nothing, depending entirely on their data and the regulator's final decision.
AKIMA Market Segment Index - Pharma eyes
Outlook Therapeutics (OTLK) is a biopharmaceutical company seeking to commercialize ONS-5010 (libersibercept), the first FDA-approved ophthalmologic drug, bevacizumab, for the treatment of wet macular degeneration. The chart shows the segment average index, helping investors assess how this strategy of legalizing existing practices compares to the average.
The AKIM Index for the overall market
Outlook Therapeutics is a biopharmaceutical company seeking approval for an ophthalmic formulation of bevacizumab for the treatment of wet AMD. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this FDA resubmission story compares to overall economic trends.
